Author

D. S. Olivier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Approach:mechanistic / dynamical model· 1 Assay:protein sequence· 1

Frequent Co-Authors

D. Willbold· 2 shared M. S. Amaral· 2 shared R. J. Eberle· 2 shared R. K. Arni· 2 shared H. Schaal· 1 shared I. Gering· 1 shared L. Mueller· 1 shared M. A. Coronado· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

D. Willbold

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivNov 10, 2021

Design of D-amino acids SARS-CoV-2 Main protease inhibitors using the cationic peptide from rattlesnake venom as a scaffold

R. J. Eberle, I. Gering, M. Tusche…·M. Coronado

The paper designs D-amino acid-based inhibitors of SARS-CoV-2 3CLpro using a rattlesnake venom peptide scaffold, showing in vitro and in vivo antiviral activity.

DOI 10.3390/ph15050540

protein sequenceexperimental assay

𝕏 PostBluesky

BiochemistrybioRxivNov 11, 2020

The repurposed drugs suramin and quinacrine inhibit cooperatively in vitro SARS-CoV-2 3CLpro

R. J. Eberle, D. S. Olivier, M. S. Amaral…·M. A. Coronado

This study shows that quinacrine and suramin inhibit SARS-CoV-2 3CLpro synergistically in vitro through competitive and non-competitive mechanisms.

DOI 10.3390/v13050873

mechanistic / dynamical modeldrug response / drug discovery

𝕏 PostBluesky